Search

for
Search:

Sort by

Research

510-540 / 1000+ results

Multidimensional Assessment of Adverse Events of Finasteride: A Real-World Pharmacovigilance Analysis Based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

research Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

August 2024 in “medRxiv (Cold Spring Harbor Laboratory)”

Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.

The FDA Approves Litfulo® (Ritlecitinib) for the Treatment of Severe Alopecia Areata in Adolescents and Adults

research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos

September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)”

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

research 484 FDA cleared devices produce inconsistent platelet-rich plasma product

June 2020 in “Journal of Investigative Dermatology”

FDA-cleared devices often fail to produce high-quality platelet-rich plasma consistently.

FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire and Function in Women

research FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire/Function in Women

April 2020 in “Online journal of complementary & alternative medicine”

Some medications can help increase sexual desire and function in women.

research Novel acne cream seeks FDA approval

October 2019

A new acne cream effectively reduced acne in trials and awaits FDA approval.

research FDA approves label addition for PDE-5 inhibitor

October 2013 in “Urology Times eNews”

The FDA approved using Cialis with Proscar for better treatment options.

research FDA declines approval of testosterone drug for third time

January 2013

The FDA did not approve a testosterone drug because of safety concerns.

research Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea

September 2015 in “Korean Journal of Clinical Pharmacy”

Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.

research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods

42 citations , April 2021 in “Pharmaceuticals”

Five FDA-approved drugs may help block COVID-19 virus entry.

research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature

1 citations , September 2022 in “Nepal journal of dermatology, venereology & leprology”

Apremilast shows promise for several skin conditions but needs more research.

Repurposing FDA Approved Drugs for Psoriasis Indications Through Integrated Molecular Docking, One-SVM Algorithm, and Molecular Dynamics Simulation Approaches

research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches

July 2025 in “Scientific Reports”

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

research Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods

November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)”

Five FDA-approved drugs may help block COVID-19 virus entry.

research Not Its Crowning Glory: Obstacles for FDA in Regulating Ingested Dietary Supplements Purporting to Prevent Hair Loss

January 2005 in “Digital Access to Scholarship at Harvard (DASH) (Harvard University)”

The FDA struggles to regulate hair loss supplements due to a law allowing unproven claims.

The Possible Role of Prescribing Medications in Contributing to Male-Factor Infertility: Assessment of the FDA Pharmacovigilance Database

research The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database

November 2023 in “Brain Sciences”

Some medications might contribute to male infertility, with finasteride showing a high number of reports.

Repurposing of Linagliptin and Similar FDA Approved Drugs as Antidiabetic Agents

research Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents

May 2021 in “Letters in Applied NanoBioScience”

Pranlukast and mirabegron may work as new diabetes drugs.

research The US FDA has approved the marketing of generic finasteride 5mg tablets by Actavis.

May 2007 in “Inpharma Weekly”

research Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System

11 citations , July 2020 in “Scientific Reports”

Statins may be linked to reproductive organ conditions, and their risks should be monitored.

Safety Concerns of Paternal Drug Exposure on Fertility, Pregnancy, and Offspring: An Analysis Based on the FDA Adverse Event Reporting System

research Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system

October 2024 in “Andrology”

Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.

research 112 Post-Finasteride Syndrome – Outcomes of FDA Database

April 2016 in “The Journal of Sexual Medicine”

research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system

30 citations , January 2024 in “Frontiers in Pharmacology”

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024

8 citations , May 2025 in “Pharmaceuticals”

In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.

research Inconsistent platelet-rich plasma product from devices cleared by the US FDA: A retrospective review of clinic data

6 citations , January 2021 in “Journal of the American Academy of Dermatology”

PRP treatments for hair loss need standard protocols to be reliable.

research Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules

3 citations , July 2022 in “BMC chemistry”

The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.

research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system

2 citations , August 2025 in “Scientific Reports”

Pexidartinib often causes liver issues and fatigue, especially in women.

research Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

1 citations , August 2024 in “Expert Opinion on Drug Safety”

Finasteride is most linked to drug-induced erectile dysfunction.

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

March 2026 in “The Aging Male”

PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.

Drugs Associated the Most with Male-Factor Infertility: Assessment of the 2010-2020 Food and Drug Administration Pharmacovigilance Database

research PD29-07 DRUGS ASSOCIATED THE MOST WITH MALE-FACTOR INFERTILITY: ASSESSMENT OF THE 2010-2020 FOOD AND DRUG ADMINISTRATION (FDA) PHARMACOVIGILANCE DATABASE

August 2021

Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.

Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System

research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)

April 2020 in “Sleep”

Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.

Post Finasteride Syndrome: Demographics from FDA Database

research 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database

April 2016 in “The Journal of Sexual Medicine”

Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.

A Microscopy-Based Small Molecule Screen in Primary Neurons Reveals Neuroprotective Properties of the FDA-Approved Anti-Viral Drug Elvitegravir

research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir

3 citations , September 2020 in “Molecular Brain”

The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.

← Previous page Next page →